Market closedNon-fractional
Century Therapeutics/IPSC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Ticker
IPSC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Philadelphia, United States
Employees
159
Website
www.centurytx.com
IPSC Metrics
BasicAdvanced
$201M
Market cap
-
P/E ratio
-$2.22
EPS
1.40
Beta
-
Dividend rate
Price and volume
Market cap
$201M
Beta
1.4
Financial strength
Current ratio
12.438
Quick ratio
12.051
Long term debt to equity
24.876
Total debt to equity
26.122
Interest coverage (TTM)
-914.77%
Management effectiveness
Return on assets (TTM)
-19.32%
Return on equity (TTM)
-58.66%
Valuation
Price to revenue (TTM)
104.648
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-1.453
Growth
Revenue change (TTM)
-76.63%
Earnings per share change (TTM)
3.33%
3-year earnings per share growth (CAGR)
-35.52%
What the Analysts think about IPSC
Analyst Ratings
Majority rating from 6 analysts.
IPSC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$800K
300.00%
Net income
-$28M
-28.75%
Profit margin
-3,500.00%
-82.19%
IPSC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.56
-$0.55
-$0.65
-$0.45
-
Expected
-$0.54
-$0.51
-$0.55
-$0.50
-$0.46
Surprise
2.89%
7.30%
17.27%
-10.36%
-
IPSC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Century Therapeutics stock?
Century Therapeutics (IPSC) has a market cap of $201M as of July 27, 2024.
What is the P/E ratio for Century Therapeutics stock?
The price to earnings (P/E) ratio for Century Therapeutics (IPSC) stock is 0 as of July 27, 2024.
Does Century Therapeutics stock pay dividends?
No, Century Therapeutics (IPSC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Century Therapeutics dividend payment date?
Century Therapeutics (IPSC) stock does not pay dividends to its shareholders.
What is the beta indicator for Century Therapeutics?
Century Therapeutics (IPSC) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Century Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.